Knockdown of ISOC1 inhibits the proliferation and migration and induces the apoptosis of colon cancer cells through the AKT/GSK-3β pathway

Bo Gao¹, LianMei Zhao², FeiFei Wang¹, HanYu Bai², Jing Li¹, Meng Li¹, XuHua Hu¹, Jian Cao¹, and GuiYing Wang¹,³,*

¹The Second General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China, ²Scientific Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China and ³Department of General Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang 050000, China

*To whom correspondence should be addressed. Tel: +86 0311 86095347; Fax: +86 0311 86032788; Email: wangguiyingtgzy@163.com

Abstract

Isochorismatase domain-containing 1 (ISOC1) is a coding gene that contains an isochorismatase domain. The precise functions of ISOC1 in humans have not been clarified; however, studies have speculated that it may be involved in unknown metabolic pathways. Currently, it is reported that ISOC1 is associated with breast cancer. In this research, the aim is to investigate the critical role of ISOC1 in colorectal cancer (CRC) and to explore its biological function and mechanism in colon cancer cells. In 106 paired clinical samples, we found that the levels of ISOC1 expression were widely increased in cancer tissues compared with matched adjacent non-tumor tissues and that increased expression of ISOC1 was significantly associated with tumor size, tumor invasion, local lymph node metastasis and Tumor, Node and Metastasis (TNM) stage. Moreover, higher expression levels of ISOC1 were correlated with shorter disease-free survival in patients 2 years after surgery. In vitro, ISOC1 knockdown inhibited the proliferation and migration and induced the apoptosis of colon cancer cells, and in vivo, the xenograft tumors were also inhibited by ISOC1 silencing. We also used MTS, Transwell and cell apoptosis assays to confirm that ISOC1 plays a critical role in regulating the biological functions of colon cancer cells through the AKT/GSK-3β pathway. Additionally, the results of confocal microscopy and western blot analysis indicated that ISOC1 knockdown could promote p-STAT1 translocation to the nucleus.

Introduction

Global cancer statistics estimates for 2018 showed that colorectal cancer (CRC) was the third most commonly diagnosed cancer and the second leading cause of cancer-related death (1). Clinical data showed that there was a higher proportion of patients with de novo metastatic disease, and even after chemotherapy, approximately 25–30% of patients with stage II/III disease had a recurrence within 5 years of surgery (2). CRC also has a high incidence in China (3). It is worth noting that the case-fatality ratio of CRC in China is 14%, which is higher than the global average of 12.2%, and the mortality/incidence ratio in China is 52.1%, which is higher than the global average of 48.3% (4). Therefore, we have to explore more effective treatment methods.

Received: February 12 2019; Revised: October 29 2019; Accepted: November 18 2019

© The Author(s) 2019. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
development via targeting by miR-130a, which forms a complex with other target proteins to affect metabolism (8). There has been relatively little research on the role of ISOC1 in cancer; however, a tumor-related protein (p16INK4a), which is homologous to ISOC1, was identified in the rat liver (9). As a multiple tumor suppressor, p16INK4a could be inhibited by overexpressing ISO2, suggesting that, as another member of the same family as ISOC1, ISO2 may play a role during tumor development (10). Previous studies have reported that the relationship between ISO1 and tumors, including the expression of ISOC1 in leiomyoma, was significantly higher than that in normal myometrium (11), ISOC1 was more abundantly expressed in ERα-positive breast cancer tissues than in ERα-negative tissues (12), and ISO1 knockdown impaired the growth of breast cancer cells (13). However, the role of ISO1 in CRC is still unknown. The purpose of this study was to clarify the expression of ISOC1 in CRC and colon cancer cell lines and the role and potential mechanism of ISOC1 in colon cancer cells.

Materials and methods

Patients and tissue samples
Legally effective informed consent was obtained from all patients whose samples were used in this study, and ethics committee approval for this study was also obtained. In this study, all 106 patients with CRC received surgical treatment in the Second General Surgery of the Fourth Hospital of Hebei Medical University from July 2015 to October 2018. Patients with primary CRC in stages I–IV, based on the seventh edition of the American Joint Commission on Cancer Staging System (AJCC), and complete clinicopathologic data met the inclusion criteria. Patients who underwent preoperative radiotherapy, chemotherapy or biological therapy were excluded. All 106 paired CRC tissue samples included tumor tissue specimens (confirmed by pathological diagnosis) and matched adjacent non-tumor tissue specimens (at least 5 cm away from the edge of the tumor mass). Patients with a postoperative period of 24 months were followed up, and the data obtained were used for disease-free survival probability analysis.

Cell culture and drug treatment
NCM460, a healthy human colon mucosa cell line, was obtained from INCELL (San Antonio). HCT116, SW480, HT-29, RKO and DLD-1 human colon cancer cell lines were purchased (6–12 months prior to experiments) from Type Culture Collection of the Chinese Academy of Science (Shanghai, China). At the time of purchase, all cell lines were examined for mycoplasma by a commercially available test kit (ProProlab; Progen Biotechnik GMBH, Germany).

Cell infection and transfection
The effective RNA interference ISOC1 target sequences 1 (5′-ATGGTACGAGGCATTATA-3′) and 2 (5′-CCCAAGTACAGGACGCGCTGTATTA-3′) were designed by GeneChem Co., Ltd. The negative control (NC) had a non-targeting sequence (5′-TTTCTCGAACGTGTCACGT-3′). The short-hairpin structural RNA (shRNA) with the NC sequence (shCtrl) or the ISOC1-targeting sequences (shISOC1-1 and shISOC1-2) were inserted into the vector (Supplementary Material 1, available at Carcinogenesis Online), which stably expressed shRNA and a marker (EGFP). This vector was used to prepare lentivirus. Small interfering RNA targeting AKT and its phosphorylation site (AKT Thr308) of deletion and activation plasmids were synthesized and purchased from GenePharma Co., Ltd and GeneChem Co., Ltd, respectively (Supplementary Materials 2 and 3, available at Carcinogenesis Online).

The cells were infected with lentivirus or transfected with small interfering RNA and plasmids, and the entire procedure followed the manufacturer’s instructions (Supplementary Methods 1 and 2, available at Carcinogenesis Online). The infected cells with green fluorescence could be observed with fluorescence microscopy (Nikon Eclipse TE2000-U, Japan).

Western blot analysis
Equal amounts of the different protein samples were electrophoretically separated by using sodium dodecyl sulfate–polyacrylamide gel electrophoresis with a 10–12% gel and then transferred onto a PVDF membrane (Millipore). After blocking the membrane in a TBS solution with 5% fat-free milk, the membranes were incubated with primary antibodies: Goat anti-rabbit IgG (611-131-122, ROCKLAND) was used as the secondary antibody. The blots were visualized by an LI-COR Odyssey 9120 Infrared Imaging System (LI-COR Biosciences). The antibodies used for the western blotting included GAPDH (AP0663, Bioworld), ISOC1 (ab118245, Abcam), AKT1/2/3 (ET1609-51, Huabio, China), P-AKT Thr308 (AF3262, Affinity), P-GSK-3β Ser9 (AF2016, Affinity), and P-STAT1 Tyr701 (AF6300, Affinity, PARPi (1337-1-AP, ProteinTech), Caspase-3 (9662, CST), Caspase-8 (GB-11594, Servicebio, China), Caspase-9 (GB-11053-1, Servicebio, China), c-Myc (5605s, CST), MMP2 (4022s, CST), MMP9 (3852s, CST).

Cell growth and proliferation assays
Cell growth assays were performed using a Celigo Image Cytometer (Nexcelom) to monitor the growth of cell numbers. After infection, cells in the logarithmic growth phase were seeded in triplicate in 96-well plates with a density of 2000 cells/well. Then, the cell images were captured, and the number of cells was calculated once a day for 5 days. Finally, the cell growth over 5 days was plotted to create a growth curve.
An MTS assay was performed to examine the proliferation of HCT-116 and SW-480 cells. Briefly, cells were plated in 96-well plates at a density of 2000/well, and the absorbance at 492 nm (OD value) was detected after 1, 2, 3, 4 and 5 days with a microplate reader after treatment with MTS solution (20 pl/well). The experiment was repeated three times, and the ratio of the OD value (days 1–5) to the average value of the first day (cell viability) was calculated and plotted as MTS curves.

**Clone-forming cell assay**

The cells were seeded in six-well plates at a density of 2000 cells per well. After 10 days of cultivation, the cells were fixed with 4% paraformaldehyde and stained with Giemsa. Then, images of the cell plates were captured, and the colonies were counted; the experiment was repeated three times.

**Caspase-3/7 activity assay and cell apoptosis analysis**

The cells were seeded in a 96-well plate with 10^4 cells/well, with a blank control well without cells. Then, Caspase-Glo (G8091, Promega) was added to each well, shaken for 30 min and incubated for 2 h at room temperature. After infection, the cells (5.0 × 10^5/well) were seeded in six-well plates. Media without serum was added to each well, shaken for 30 min and incubated for 2 h at room temperature. The Caspase-Glo 3/7 assay releases a substrate of luciferase after being cleaved by caspase-3 and -7. The substrate of luciferase results in a luminescent signal that can be detected by a Synergy 2 Multi-Mode Reader (BioTek).

Annexin V-APC (88-8007-72, eBioscience) was used for cell staining in the cell apoptosis assay. According to the manufacturer's instructions, the cells (≥5 × 10^5/well) were washed, digested and then resuspended with 200 µl binding buffer. Then, 10 µl annexin V-APC was added to 200 µl cell suspension and incubated in the dark at room temperature for 10–15 min. Cell apoptosis analysis was detected by a Guava easyCyte HT cytometer (Millipore).

**Wound healing assay and Transwell migration assay**

After infection, the cells (5.0 × 10^5/well) were seeded in six-well plates. Cells were allowed to grow to >80% confluence, then a pipette tip (200 µl) was used to scrape the cell layer of each culture plate to create scratch wounds. To inhibit cell division, serum-free medium containing 1 µM mitomycin was used to replace the complete medium. Phase-contrast images of wound fields were obtained at 0, 24 and 48 h after scratching.

Transwell migration assays were also used to test cell mobility. The cells were seeded on a non-coated membrane located in the upper chamber of a well in 24-well plates. Media without serum was added to the upper chamber, whereas media with 10% fetal bovine serum was added to the lower chamber to act as a chemoattractant for cell migration. After 24 h of incubation, cells that had not migrated were on the upper surface of the membrane, whereas the cells on the other side of the membrane were stained with crystal violet. The number of cells in five random fields of view was counted. Both experiments were repeated three times.

**Animal experiments**

Male BALB/c nude mice were purchased (Beijing Vital River Laboratory Animal Technology Co., Ltd) and then fed by staff at the Experimental Animal Center of the Fourth Hospital of Hebei Medical University. Six-week-old mice were randomly assigned to two groups (n = 5) and were injected subcutaneously in their right flanks with 5 × 10^5 infected cells. Tumor size was measured two times a week from days 1 to 21 post-implantation. Twenty-one days after subcutaneous inoculation, all mice were killed, and their tumors were weighed. Tumor volume was calculated using the following formula: (length × width^2)/2. Animal experiments followed the USA National Institutes of Health Guidelines.

**PathScan intracellular signaling array**

PathScan was used to detect changes in key signaling molecules in signal pathways. After infection, HCT-116 cells were collected and lysed. The PathScan® Antibody Array Kit (Cell Signaling Technology, #14471) was used for detection, and the procedure was performed according to the manufacturer's instructions.

**Nuclear and cytoplasmic protein extraction**

For the extraction of nuclear and cytoplasmic protein, cells were treated with the NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo, 78833) according to the manufacturer's instructions.

**Immunocytochemistry and confocal microscopy**

After infection, the cells were grown on coverslips, fixed with 4% paraformaldehyde and blocked with 10% fetal bovine serum. The coverslips were then incubated with the indicated antibodies overnight at 4°C and then incubated with goat anti-rabbit Cy3 secondary antibody (Wuhan Servicebio Technology, China) for 50 min. DNA was stained with 4’,6-diamidino-2-phenylindole (Wuhan Servicebio Technology). Coverslip images were collected using a laser confocal microscope (Nikon Eclipse Ti, Japan).

**Statistical analysis**

Statistical analysis was performed using SPSS version 23.0 software. The mean ± SD was used to depict the experimental data. One-way analysis of variance, Student's t-tests, and the Wilcoxon signed rank test were performed for comparisons. Chi-square analyses were used to analyze categorical variables. The Kaplan–Meier method was used to estimate disease-free survival. A P-value < 0.05 was considered statistically significant, and all statistical tests were two sided.

**Results**

**ISOC1 is a CRC-associated gene and was knocked down with high efficiency by shRNA lentivirus**

Our results showed that, compared with those in the matched non-tumor tissues, the mRNA expression levels of ISOC1 in cancer tissues were significantly lowered (Figure 1A, P = 0.008). The cancer genome atlas (TCGA) and Genotype-Tissue Expression (GTEx) database also showed that ISOC1 was expressed higher in CRC tissues than normal tissues (http://gepia.cancer-pku.cn/detail.php?gene=isoc1); as shown in Supplementary Figure 1, available at Carcinogenesis Online, the difference was statistically significant only in our data, but not in TCGA and GTEx data. The disease-free survival analysis was performed via the Kaplan–Meier method, which is based on the cutoff value determined using receiver operating characteristic curves. The results showed that higher ISOC1 expression levels in patients were correlated with shorter disease-free survival (Figure 1B). The median disease-free survival time for patients with CRC with high ISOC1 expression or low ISOC1 expression was 19.5 and 22.8 months, respectively. Immunohistochemical staining was used to compare the expression of ISOC1 proteins in 38 pairs of CRC tissues and matched adjacent non-tumor tissues. As summarized in Table 1, comparing the upregulated ISOC1 expression and clinical-pathological features of 106 CRC cases showed that elevated ISOC1 expression was significantly associated with tumor size, tumor invasion, local lymph node metastasis and Tumor, Node and Metastasis (TNM) stage. As shown in Figure 1C, ISOC1 staining was predominantly positive in the cytoplasm of tumor cells, whereas weak staining of ISOC1 was present in non-tumor epithelial cells. The frequency of ISOC1 positive (+++ or ++++) staining in CRC tissues (60.5%, 23 of 38 samples) was significantly higher (Supplementary Table, available at Carcinogenesis Online, χ^2 = 7.664, P = 0.006) than that in matched non-tumor tissues (28.9%, 11 of 38). Moreover, ISOC1 mRNA and protein expression were detected in NCM-460, HCT-116, SW-480, RKO, DLD-1 and HT-29 cell lines. In addition to the RKO cell line, the mRNA and protein expression of ISOC1 in the other colon cancer cell lines was higher than that in the normal colon epithelial cell line NCM460, as depicted in Figure 1D and E. The results also showed that the expression of ISOC1 was higher in the HCT-116 and SW-480 cells than in the other three colon cancer cell lines. Thus, HCT-116 and SW-480 were chosen for further experiments.

**ISOC1 was downregulated in ISOC1-shRNA cell lines, and knockdown of ISOC1 inhibited colon cancer cell proliferation**

To clarify the biological effect of ISOC1, we infected HCT-116 and SW-480 cell lines with the ISOC1-shRNA or NC lentivirus.
Approximately 72 h later, the percentage of cells with green fluorescence suggested infection efficiency is greater than approximately 80% (Supplementary Figure 2, available at Carcinogenesis Online). After approximately 72–120 h, the cells were harvested, and total proteins and RNAs were collected. The qRT–PCR results suggested that compared with that in Figure 1. ISOC1 expression in ygjuikf samples NNNNNNNNk/0124528 cell lines. (A) ISOC1 expression was analyzed by qRT–PCR in 106 paired samples including tumor and adjacent non-tumor tissues. Statistical analysis was performed using the Wilcoxon signed ranks test, and the horizontal line indicates the median value. (B) The patient’s 2-year disease-free survival (DFS) data, which were analyzed by the Kaplan-Meier method, were used to reflect the effect of the ISOC1 expression level on clinical prognosis. The survival probability of the ISOC1-high expression group (n = 49) was significantly lower than that of the ISOC1-low expression group (n = 23; log-rank test; P = 0.006). The cutoff threshold of ISOC1 expression is determined using the Youden index of receiver operating characteristic curves. (C) Representative immunohistochemistry staining of ISOC1 in CRC tissues and adjacent non-tumor tissues (×400). Negative: −~++; Positive: ++~+++. (D, E) ISOC1 mRNA and protein expression levels in colon cancer cell lines.
Table 1. Correlation between ISOC1 expression and clinicopathologic features in 106 CRC patients

| Clinicopathologic features | ISOC1 Low | ISOC1 High | χ²  | P-value |
|---------------------------|-----------|------------|-----|---------|
| All                       | 53        | 53         | 0.151 | 0.697   |
| Age ≥62                   | 27        | 29         |      |         |
| Age >62                   | 26        | 24         |      |         |
| Gender Male               | 23        | 20         | 1.873 | 0.171   |
| Gender Female             | 16        | 19         |      |         |
| Tumor size ≤5 cm          | 39        | 27         | 5.782 | 0.016*  |
| Tumor size >5 cm          | 14        | 26         |      |         |
| Tumor Invasion T1 + T2    | 10        | 2          | 6.526 | 0.011*  |
| Tumor Invasion T3 + T4    | 43        | 51         |      |         |
| N stage N0                | 37        | 24         |      |         |
| N stage N1 + 2            | 16        | 29         |      |         |
| M stage M0                | 52        | 0          | 1.334 | 0.248   |
| M stage M1                | 50        | 3          |      |         |
| TNM stage +II             | 36        | 23         | 6.46  | 0.011*  |
| TNM stage +IV             | 17        | 30         |      |         |
| Tumor embolus Positive    | 8         | 9          | 0.07  | 0.791   |
| Tumor embolus Negative    | 45        | 44         |      |         |
| Pathological differentiation Well moderate | 50       | 47         | 1.093 | 0.488   |
| Pathological differentiation Poor     | 3         | 6          |      |         |

χ² tests were used to analyze the correlation between the expression level of ISOC1 and clinical features. The median expression level was used as the cutoff. Low expression of ISOC1 in 53 patients was classified as values below the 50th percentile. High ISOC1 expression in 53 patients was classified as values above the 50th percentile.

*P < 0.05 indicates the statistical significance.

Furthermore, the results of the colony formation assay showed that ISOC1 knockdown induced a substantial reduction in the colony formation ability of HCT-116 and SW-480 cells (Figure 2D).

ISOC1 knockdown induced apoptosis in colon cancer cells

Caspase-3/7 activity and cell apoptosis assays were employed to investigate the effect of ISOC1 knockdown on apoptosis in colon cancer cells. As shown in Figure 3A, the relative caspase-3 and -7 activities were significantly higher in the ISOC1 knockdown groups than in the NC group. The results of the cell apoptosis assay suggested that the apoptosis rate of HCT-116 and SW-480 cells was dramatically increased in the ISOC1 knockdown groups compared with the NC group (Figure 3B). Based on the experiments shown here, ISOC1 may be related to the apoptosis of colon cancer cells. To explore the potential mechanism, the protein expression of PARP1 and caspase-3, -8 and -9 was examined. The results showed that, compared with that in the NC cells, the expression of cleaved PARP1 and cleaved caspase-3 and -9 in ISOC1 knockdown cells was increased, whereas the full lengths of these proteins were decreased. There was no significant difference in the expression of caspase-8 (Figure 3C).

The migration of colon cancer cells in vitro was inhibited by ISOC1 knockdown

The effect of ISOC1 on colon cancer cell migration was assessed by wound healing and Transwell migration assays. The results of the wound healing assay showed that, at 48 h after the scratch, HCT-116 or SW-480 cells that were NC lentivirus-infected almost completely closed the gap, whereas wounds were much slower to heal in cells infected with ISOC1 shRNAs (Figure 3D). The results of the Transwell migration assays suggested that after 24 h, the number of cells penetrating the membrane in the ISOC1 knockdown groups was significantly less than that in the NC group (Figure 3E). The wound healing and Transwell assays demonstrated that the migration capability of colon cancer cells was inhibited by ISOC1 silencing.

Knockdown of ISOC1 inhibited xenograft tumor growth in vivo

To investigate the effect of ISOC1 on the tumorigenicity of colon cancer cells in vivo, HCT-116 cells treated with ISOC1 shRNA (shISOC1-1) or NC lentivirus were subcutaneously implanted into nude mice (Supplementary Figure 3, available at Carcinogenesis Online). As shown in Figure 4A, the images showed that tumor growth in mice treated with ISOC1 shRNA was dramatically decreased compared with that of the NC group (Figure 2A). The results showed that, compared with that in the NC group (shCtrl group), the expression of ISOC1 in the knockdown groups (shISOC1-1 and shISOC1-2 groups) was reduced by approximately 75% in both cell lines. The results of the western blot assay showed that the protein level of ISOC1 was greatly reduced by infecting with ISOC1 shRNAs (Figure 2D). Furthermore, the results of the colony formation assay demonstrated that ISOC1 knockdown inhibited xenograft tumor growth (Figure 3A).

Knockdown of ISOC1 inhibited xenograft tumor growth in vivo

To investigate the effect of ISOC1 on the tumorigenicity of colon cancer cells in vivo, HCT-116 cells treated with ISOC1 shRNA (shISOC1-1) or NC lentivirus were subcutaneously implanted into nude mice (Supplementary Figure 3, available at Carcinogenesis Online). As shown in Figure 4A, the images showed that tumor growth in mice treated with ISOC1 shRNA was dramatically decreased compared with that of the NC group (Figure 2A). The results showed that, compared with that in the NC group (shCtrl group), the expression of ISOC1 in the knockdown groups (shISOC1-1 and shISOC1-2 groups) was reduced by approximately 75% in both cell lines. The results of the western blot assay showed that the protein level of ISOC1 was greatly reduced by infecting with ISOC1 shRNAs (Figure 2D). Furthermore, the results of the colony formation assay demonstrated that ISOC1 knockdown inhibited xenograft tumor growth (Figure 3A).

Loss of ISOC1 affected the biological functions of colon cancer cells through the AKT/GSK-3β pathway and promoted the expression of p-STAT1 in the nucleus

To investigate the underlying signaling pathways mediated by ISOC1, the PathScan intracellular signaling array kit was utilized to detect 18 important signaling molecules in HCT-116 cell lines after ISOC1 knockdown (Figure 4D). The alterations that occurred in pivotal signaling proteins are shown in Figure 4F. The levels of cleaved PARP and caspase-3 and the levels of phosphorylated
AKT Thr308, GSK-3β Ser9, STAT1 Tyr701 and AMP-activated protein kinase α Thr172 (AMPKα Thr172) were obviously increased in ISOC1 knockdown cells compared with NC cells. The level of phosphorylated AKT Ser473 was not significantly increased.

Studies have shown that GSK-3β has tumor-promoting effects in colon cancer (14,15); however, GSK-3β activity was inhibited by phosphorylation at Ser9 of GSK-3β (16,17). Akt mediates the induction of an inactive form of GSK-3β by phosphorylating its Ser9 residue (18). Thus, we first determined the results of the PathScan array by using western blotting (Figure 4G). Then, we used UCN01, which can inhibit phosphorylation of AKT at Thr308 (19), to conduct mechanistic research in colon cancer cells. As shown in Figure 4H, after 20 min of treatment with UCN01, the protein levels of p-AKT at Thr308 in the ISOC1 knockdown cells decreased as the concentration of UCN01 increased. To reduce the effect of UCN01 alone on the experimental outcome, we administered UCN01 at the lowest possible effective dose of 100 nM. We also examined earlier time points and determined that there was a significant decrease in phospho-GSK-3β at Ser9 in the UCN01-treated cells after applying UCN01 for approximately 2 h (Figure 4I). Then, we divided the ISOC1 knockdown and NC group cells into four groups in the presence and absence of UCN01: shCtrl, shCtrl+UCN01, shISOC1, shISOC1 + UCN01. We further applied the MTS, Transwell and cell apoptosis assays...
(Figure 5A–C) to confirm the effect of ISOC1 on the biological behavior of colon cancer cells through the AKT/GSK-3β pathway. The proliferation, migration and apoptosis abilities of the ISOC1 knockdown cells were reversed after p-AKT Thr308 and p-GSK-3β Ser9 expression was suppressed with UCN01. At the same time, in the ISOC1 knockdown cells, we downregulated the mRNA and protein levels of AKT using small interfering RNA; however, the results of MTS (Supplementary Figure 4, available at Carcinogenesis Online) showed that downregulation of total AKT protein could not rescue the inhibition of colon cancer cell proliferation caused by ISOC1 silencing. Subsequently, we verified that the protein level of p-GSK-3β Ser9 could be upregulated...
Figure 4. Knockdown of ISOC1 inhibits colon cancer cell growth in vivo and alters signaling proteins in colon cancer cells. (A) The tumors at day 21. HCT-116 cells infected with NC (shCtrl) or ISOC1-shRNA (shISOC1) lentivirus were subcutaneously implanted into nude mice, and 21 days later, the tumors were excised. (B) Tumor volumes were calculated in each group every 3 days from day 1 to day 21. (C) Tumor weights were measured on day 21. The error bars represent the standard deviation; *P < 0.05, **P < 0.01. (D) Representative immunohistochemical staining of ISOC1-shRNA (shISOC1) and NC (shCtrl) groups (×400). (E) PathScan assay. Eighteen pivotal signaling proteins were detected by the PathScan intracellular signaling array kit. (F) The upregulated proteins after silencing ISOC1. (G) Western blot assay. The protein levels of p-AKT Thr308 and p-GSK-β Ser9 were increased in the shISOC1 group compared to the shCtrl group. (H, I) Western blot assay. The protein levels of p-AKT Thr308 and p-GSK-β Ser9 decreased with UCN01 treatment (100/nM) in ISOC1 knockdown cells. The error bars represent the standard deviation; *P < 0.05, **P < 0.01.
Figure 5. The effects of ISOC1 knockdown on the biological function of colon cancer cells are rescued by UCN01. Further verification of the mechanism of ISOC1 in colon cancer cells. The protein level of p-STAT T yr701 in colon cancer cell nuclei was increased by ISOC1 knockdown. (A) MTS assays. (B) Transwell migration assays. (C) Cell apoptosis assay. (D) Western blot assay. The protein level of p-GSK-3β Ser9 was upregulated by overexpression of p-AKT Thr308. AKTΔ-Thr308: p-AKT Thr308 deletion plasmid. AKTP-Thr308: p-AKT Thr308 activation plasmid. (E) Western blot assay. The protein levels of c-Myc, MMP2 and MMP9 were significantly reduced by ISOC1 knockdown. (F) Confocal microscopy and western blot analysis of p-STAT1 T yr701 nuclear localization. Green signals represent cells infected with lentiviruses. DNA was visualized with 4′,6-diamidino-2-phenylindole (DAPI) (blue). Western blot analysis showed that the protein levels of p-STAT1 T yr701 were increased in the shISOC1 group compared to the shCtrl group. The error bars represent the standard deviation. *P < 0.05, **P < 0.01.
by overexpression of p-AKT Thr308 (Figure 5D). These results indicate that ISOC1 may affect colon cancer cells by partially activating AKT. To further explore the potential mechanism of ISOC1 knockdown effects on proliferation and migration, c-Myc, MMP2 and MMP9 protein levels were examined. As shown in Figure 5E, after downregulating ISOC1 in HCT-116 and SW-480 cells, the protein levels of c-Myc, MMP2 and MMP9 were significantly reduced.

STAT1 has been shown to have tumor-suppressive activity by inhibiting tumor angiogenesis, growth and metastasis (20). To investigate the effects of ISOC1 on STAT1, we examined the p-STAT1 Tyr701 protein level in ISOC1 knockdown HCT-116 and SW-480 cells. The western blotting results confirmed the observations made by immunofluorescence: compared with NC cells, ISOC1 knockdown obviously increased the levels of nuclear STAT1 protein (Figure 5F).

**Discussion**

CRC patients, even terminal cancer patients, have benefited from new advances over the past decade, including molecular characterization and application of targeted agents, etc (21). However, worldwide, CRC is still one of the highest ranked malignant tumors by morbidity and mortality rates. Researchers are attempting to search for novel molecular features and unravel the underlying mechanisms of cancer formation.

ISOC1 contains an isochorismatase domain that may be involved in the hydrolysis of ether bonds. The conversion of isochorismate to 2,3-dihydroxybenzoate and pyruvate is catalyzed by isochorismatase. Previously, this process was found to be a part of the shikimic acid pathway in microorganisms (22); however, ISOC1 and its homologs were also found in mammals (23, 24). Thomas Gronemeyer et al. (23) reported five peroxisome-associated proteins in humans, including ISOC1, and further analysis may facilitate the discovery of new metabolic pathways. Reprogramming of energy metabolism is one of the 10 hallmarks of cancer (25), and studies (26–28) have also suggested that the diversity and complexity of metabolic mechanisms in cancer cells are beyond our understanding. It has been reported that cancer cells are able to increase glucose import into the cytoplasm, and most of the decomposed pyruvic acid is used for glycolysis in the cytoplasm (29–31). Aerobic glycolysis has also been reported for many years, indicating that even in an aerobic environment, cancer cellular energy is produced largely through glycolysis (25), and the intermediate product of glycolysis is likely to provide raw materials for assembling more new cells (32). Whether ISOC1 overexpression is involved in assembling more new cancer cells or in unknown energy metabolism mechanisms of cancer requires further study.

To better understand the role of ISOC1 in CRC, we conducted a preliminary study. Initially, we confirmed that compared with matched non-tumor tissues, ISOC1 expression was widely increased in cancer tissues and that the increased expression of ISOC1 was significantly associated with tumor size, tumor invasion, local lymph node metastasis and TNM stage. Then, patients were followed up for 2 years after the operation, and we found that higher expression levels of ISOC1 were correlated with shorter disease-free survival time. In addition, due to the small amount of transcriptome sequencing in normal CRC tissues in TCGA database, we combined TCGA and GTEx databases and obtained more data from them. In TCGA and GTEx database, we also found that the expression of ISOC1 in CRC tissues is higher than that in normal tissues, but it is not statistically significant. The difference between this result and our experiment may be due to the small sample size in the database or our experiments or the difference in the selected samples leading bias in the statistical results.

In the *in vitro* experiments, proliferation and migration were inhibited, and apoptosis was induced after ISOC1 knockdown in colon cancer cells. Furthermore, the xenograft tumors were also inhibited by ISOC1 silencing in vivo. We first explored how ISOC1 affects apoptosis-related proteins. The caspase family plays a central role in apoptosis (33), and the PARP1 protein contributes to 90% of the total cellular PARP activity (36). Our results showed that ISOC1 silencing may induce the apoptosis of colon cancer cells through the mitochondrial pathway.

As mentioned in the PathScan results, the expression of some key proteins in signaling pathways was increased after ISOC1 silencing; among these proteins, the role of AMPK in the tumor remains controversial (37). Phosphorylation of Akt at Thr308 leads to a substantial but incomplete activation of Akt (38, 39), maximal activation requires additional phosphorylation at Ser473; however, the protein level of p-Akt Ser473 was not significantly increased. As mentioned above, GSK-3β has tumor-promoting effects in colon cancer, Akt mediates inactivation of GSK-3β by phosphorylating its Ser residues, and the Akt inhibitor UCN01 inhibits phosphorylation of Akt at Thr308. Thus, we used UCN01 to inhibit the activity of p-AKT Thr308 and GSK-3β Ser473 and confirmed that ISOC1 plays a critical role in colon cancer cells through the Akt/GSK-3β pathway by using MTS, Transwell and cell apoptosis assays. Additionally, in our study, downregulation of total Akt protein did not rescue the inhibition of colon cancer cell proliferation that was mediated by silencing of ISOC1. We speculate that this may be due to the partial activation of Akt caused by ISOC1 knockdown. To verify this, we overexpressed the protein level of p-AKT Thr308 in HCT-116 and SW-480 cell lines and found that the protein level of p-GSK-3β Ser473 increased significantly. To further explore the specific mechanism of ISOC1 on proliferation, apoptosis and migration of colon cancer cells, the protein levels of c-Myc, MMP2 and MMP9 were measured. C-Myc belongs to the MYC family, and its high expression is closely related to the growth and proliferation of cancer cells; it also participates in apoptosis resistance as a substrate for GSK-3β (40–42). MMP2 and MMP9 belong to the matrix metalloproteinase family and have important roles in cancer cell migration, invasion and metastasis (43, 44). The results showed that the levels of the three proteins were significantly reduced after silencing ISOC1.

STAT1, which belongs to the STAT family, is a tumor suppressor gene (45, 46), and the STAT1-containing complex can translocate to the nucleus to participate in cell proliferation, survival, apoptosis and differentiation. It requires phosphorylation at both Tyr701 and Ser727 for full activation (47). One study has reported that abrogation of STAT1 reversed antiproliferative effects in colon cancer cells (48). We found that silencing ISOC1 led to nuclear transposition of p-STAT1 Tyr701 in colon cancer cells, as revealed by confocal imaging and western blotting.

In conclusion, all of these results provide evidence that ISOC1 expression levels in CRC tissues are higher than those in matched non-tumor tissues. ISOC1 overexpression was associated with tumor size, tumor invasion, local lymph node metastasis and TNM stage. The higher expression of ISOC1 levels was correlated with shorter disease-free survival. ISOC1 was confirmed to play an important role in regulating colon cancer cell proliferation, migration and apoptosis through the Akt/GSK-3β pathway, and a high level of nuclear p-STAT1 Tyr701 was frequently found in ISOC1 knockdown cells of colon cancer. ISOC1 may be a prognostic factor and therapeutic target for CRC in the future.
Supplementary material
Supplementary data are available at Carcinogenesis online.

Funding
Natural Science Foundation of China (81502032, 81673642 and 81772550).

Acknowledgements
We wish to thank LianMei Zhao for help with the manuscript and the Experimental Animal Center of the Fourth Hospital of Hebei Medical University for help with animal experiments.

Conflict of Interest Statement: All of authors declare no potential conflicts of interest.

References
1. Bray, F. et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 68, 394–428.
2. Shah, M.A. et al. (2016) Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J. Clin. Oncol., 34, 843–853.
3. Pan, R. et al.; China Kadoorie Biobank Collaborative Group. (2017) Cancer incidence and mortality: a cohort study in China, 2008–2013. Int. J. Cancer, 141, 1315–1323.
4. Zhu, J. et al. (2017) Epidemiological trends in colorectal cancer in China: an ecological study. Dig. Dis. Sci., 62, 235–243.
5. Young, I.G. (2004) 7-Hydroxystaurosporine (UCN-01) inhibits Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin. Cancer Res., 10, 7192–7198.
6. Huang, S. et al. (2002) Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene, 21, 2504–2512.
7. Looe, J.M. et al. (2017) Recent developments in the treatment of metastatic colorectal cancer. Ther. Adv. Med. Oncol., 9, 551–564.
8. Walsh, C.T. et al. (1990) Molecular studies on enzymes in chorismate metabolism and the enterobactin biosynthetic pathway. Chem. Rev., 90, 1105–1129.
9. Gronemeyer, T. et al. (2013) The proteome of human liver peroxisomes: identification of five new peroxisomal constituents by a label-free quantitative proteomics survey. PLoS One, 8, e73795.
10. Islinger, M. et al. (2007) Rat liver peroxisomes after fructose treatment. A survey using quantitative mass spectrometry. J. Biol. Chem., 282, 23055–23069.
11. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646–674.
12. Locasale, J.W. et al. (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogene. Nat. Genet., 43, 869–874.
13. Chinnaiyan, P. et al. (2012) The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res., 72, 5878–5888.
14. Ying, H. et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149, 656–670.
15. Delberardinis, R.J. et al. (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab., 7, 11–20.
16. Hsu, P.F. et al. (2008) Cancer cell metabolism: Warburg and beyond. Cell, 134, 703–707.
17. Jones, R.G. et al. (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev., 23, 537–548.
18. Vander Heiden, M.G. et al. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029–1033.
19. Rathmell, J.C. et al. (1999) The central effectors of cell death in the immune system. Annu. Rev. Immunol., 17, 781–828.
20. Kaufmann, S.H. et al. (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53, 3976–3985.
21. Tewari, M. et al. (1995) Yama/CP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell, 81, 801–809.
22. Drew, Y. et al. (2009) PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat., 12, 153–156.
23. Dasgupta, B. et al. (2016) Evolving lessons on the complex role of AMPK in normal physiology and cancer. Trends Pharmacol. Sci., 37, 192–206.
24. Alessi, D.R. et al. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase C alpha. J. Biol. Chem., 272, 421–428.
25. Pedersen, C.C. et al. (2015) Impact of microRNA-150s on the neutrophil proteome. BMC Immunol., 16, 70.
26. Kikuchi, M. et al. (2004) Proteomic analysis of rat liver peroxisome: presence of peroxisome-specific isozyme of Lon protease. J. Biol. Chem., 279, 421–428.
27. Huang, X. et al. (2007) Identification and characterization of a novel protein ISO2C that interacts with p16INK4a. Biochem. Biophys. Res. Commun., 361, 287–293.
28. Li, Z. et al. (2008) Microarray study of gene expression in uterine leiomyoma. Exp. Oncol., 30, 106–111.
29. Rezaul, K. et al. (2010) Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics. Genes Cancer, 1, 251–271.
30. Yamaga, R. et al. (2014) Systemic identification of estrogen-regulated genes in breast cancer cells through cap analysis of gene expression mapping. Biochem. Biophys. Res. Commun., 447, 531–536.
31. Shakoori, A. et al. (2007) Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci., 98, 1388–1393.
32. Mai, W. et al. (2006) Detection of active fraction of glycogen synthase kinase 3beta in cancer cells by nonradioisotopic in vitro kinase assay. Oncology, 71, 297–305.
33. Harwood, A.J. (2001) Regulation of GSK-3: a cellular multiprocessor. Cell, 105, 821–824.
34. Beurel, E. et al. (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol. Ther., 148, 114–131.
35. Sharma, M. et al. (2002) Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J. Biol. Chem., 277, 30935–30941.
36. Kondapaka, S.B. et al. (2004) 7-Hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for...